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Background: Observational studies have suggested an association between HIV infection and
emphysema.
Aims: The primary aim of this study was to estimate the prevalence of obstructive lung disease
in HIV-infected patients seen in an outpatient infectious disease clinic. The secondary aim was
to estimate the prevalence of Obstructive Lung Disease (OLD) in smokers and non smokers in
this population.
Methods: This was a prospective cross-sectional study. Consecutive patients who were seen for
routine HIV care underwent spirometry and answered the St. George’s Respiratory Question-
naire (SGRQ). Further, we collected information from the charts on demographics, co-
morbidities, CD4 cell count, and HIV viral load (current, baseline, etc).
Results: This study included 98 HIV-infected patients with mean age of 45 years, (SD: 11) and
84% male. They were seen from November 2008 to May 2009 at Thomas Jefferson University in
Philadelphia. According to established criteria, spirometry results were classified as normal in
69% and obstructive in 16.3%. Among those who never smoked, the prevalence of obstructive
lung disease on spirometry was 13.6%. The prevalence of obstruction in HIV patients with
a history of smoking was 18.5%. Current and ever smokers comprised 21.4% and 55% of the
patients respectively. The mean SGRQ total score was 7. The mean SGRQ score in active
smokers was 17 and 15 in those subjects with a prior history of smoking. The mean SGRQ score
among patients with obstruction in spiromerty was 27.7 in patients with obstruction on
spirometry.ffiliated with Wellstar Pulmonary Medicine. 55 Whitcher street Suite 160, Marietta GA 30060, USA.
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1656 A. Hirani et al.Conclusion: This urban population of HIV-infected persons has a relatively high prevalence of
obstructive lung disease as assessed by spirometry. Furthermore, the high prevalence of
obstructive lung disease in never smokers may suggest a possible association between HIV
infection and emphysema. In addition the SGRQ total score was comparatively higher in
patients with obstruction on spirometry. Our data suggests that potentially all patients with
HIV should be screened a for OLD.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
In the western world the morbidity and mortality in
patients infected with Human Immunodeficiency Virus
(HIV) infection have changed over past 3 decades. In the
early history of the epidemic, prior to the development of
anti-retroviral therapy (ART), the diagnosis of HIV infection
was frequently made when patients presented with
opportunistic infections. In more recent years ART has
provided patients a good quality of life and a decrease in
the number opportunistic infection in the developed part
of the world. In the current era, many patients have ach-
ieved control of their HIV infection, with many now
developing chronic medical conditions such as malignancy,
cardiovascular disease, diabetes mellitus, and chronic
pulmonary disease.
Due to utilization of ART therapy, we were able to ach-
ieve extended suppression of HIV viral load and attain an
impressive decline in rates of opportunistic infections,
hospitalizations, and AIDS-related death in Europe and North
America.1,2 A retrospective study has reported that patients
with HIV infection are living longer and may have multiple
co-morbidities by the age of 50, of which 16.1% had chronic
obstructive pulmonary disease (COPD).3 These patients had
multiple co-morbidities with an increased life span due to
the success of ART therapy and may require sub-specialties
of medicine like pulmonary for further care and treatment3
to improve their outcome and longevity.
Obstructive lung disease (OLD) is a group of respiratory
disease characterized by airway obstruction. It comprises
of Asthma, Bronchitis, and Chronic obstructive pulmonary
disease.
Noninfectious pulmonary conditions are becoming
increasingly common in HIV infected individuals.4 Patients
with HIV infection have an increased evidence of emphy-
sema and abnormal computer tomography images of
lung.5,6 They may also have abnormal airway responsive-
ness.7 A contributing factor to this increase could be that
HIV-infected patients in the developed world have higher
rates of smoking than the general population. Almost 75% of
patients report a smoking history, and 40e50% are current
smokers.8,9 Recent studies have shown a decline in smoking
rates but they are still higher than general population.10,11
Smoking cessation has shown a decline in mortality in the
DAD study11 and presence of OLD is associated with lower
quality of life.12
We all are aware that all smokers do not develop
obstructive lung disease. Some groups are more prone to
develop OLD, for example, deficiency in Alpha 1 anti-
trypsin.13 HIV patients may be another subset of the pop-
ulation that may at a greater risk of developing OLD.Whether HIV makes them prone to more damage from
viral infection or if the HIV virus has direct effect to cause
OLD is unknown. OLD may be emerging as an important
clinical problem in HIV-positive patients.
Recently, in a study consisting of 1014 patients infected
with HIV and 713 control patients.HIV infection was found
to be an independent risk factor for the development of
COPD.14 The prevalence of obstructive disease in this study
was determined by International classification of diseases
(ICD) 9 codes and self-reporting. However, the gold
standard for diagnosis of OLD is spirometry.
Recently a related study was published showing no
noteworthy decline in FEV1% with smoking in HIV patients.
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Identification of HIV as a risk fact for OLD could help focus
screening and interventions that might have an impact on
patient outcomes. Thus, we sought to estimate the preva-
lence of OLD in this population.Methods
We performed a cross-sectional study on a population of
HIV patients who are receiving care in an infectious disease
clinic at our university. All HIV-positive patients with or
without smoking history were offered spirometry analysis.
The Institutional review board (IRB) at Thomas Jefferson
University Hospital approved this study with control #
08D.422. All patients provided written informed consent for
participation in this study prior to the initiation of study
procedures.
Subjects
Study subjects consisted of consecutive adult outpatient
HIV-positive patients who presented for routine follow-up
with their infectious disease physicians between November
2008 and May 2009. Inclusion criteria were limited to HIV
positivity and age greater than 18 years. Subjects with
recent hospital admission for any respiratory problem were
excluded from the study. Other Exclusion criteria are listed
in Table 1.
Variables
Demographic variables including age, sex, ethnic group and
years of HIV infection were collected. Baseline information
about each patient was collected from their medical
records including anti-retroviral therapy, year of diagnosis,
any history of lung infections in past, smoking status, CD4
count, current viral load, hepatitis B and C status.
Table 1 Exclusio n Criteria.
Exclusion Criteria
1. Pregnant patients
2. Neuromuscular disorders
3. Patients with severe scoliosis
4. Patients with acute decompensated congestive
heart failure
5. Patients with recent pneumonia or lower respiratory
tract infection (within the last one month)
6. Thoracotomy, sternotomy, major cardiopulmonary
intervention (open heart surgery, etc.), or other
procedure in the 1year prior to screening likely
to cause instability of pulmonary status
7. Patients with established Lung diseases except COPD.
8. History of lung resection
Prevalence of obstructive lung disease in HIV population 1657Smoking history
Smoking history was self-reported. Patients with a smoking
history in the last 30 days were categorized as current
smokers. Ever smokers were reported as smoking cigarettes
ever in their lifetime totaling to greater than 100 cigarettes.
Spirometry
A portable spirometer with KOKO spirometry software
version 4.10 was used to perform spirometry according to
guidelines of American Thoracic Society.16
To achieve acceptable protocol curves, patients per-
formed minimum of 3 to a maximum of 8 forced expira-
tions. We sought to provide three acceptable spirograms.
The patients were seated when performing the forced
expiration maneuver. Efforts were considered acceptable if
they were free of artifacts, and had no evidence of early
termination, inconsistent effort, leak, or obstructed
mouthpiece. Acceptable spirograms required a satisfactory
initiation of effort with back-extrapolated volume not
exceeding 5% of FVC or 150 ml, whichever was larger.
Acceptability criteria also included a satisfactory exhala-
tion time of at least 6 s and/or a plateau in the volume/
time curve. Measurements were considered reproducible if
the largest and second-largest FVC or FEV1 measurements
were within 200 ml of each other.
The largest measures of FVC and FEV1 from all accept-
able spirograms were selected for data analysis. All
acceptable measures were expressed in absolute values
(liters) and as percent predicted of normal with NHANES III
predictable.17 We defined subjects with an FEV1/FVC ratio
of less than 0.70 and an FEV1 less than 80% of their pre-
dicted value as having OLD. Patients with known diagnosis
of OLD were also included in the analysis.
St. George Respiratory Questionnaire (SGRQ)
After obtaining spirometry, the subjects answered the St.
George Respiratory Questionnaire (SGRQ). The activity,
symptom and total scores were calculated for each subject
per the SGRQ instructions.18e20Laboratory data
We collected the information on the CD4 count, HIV viral load
at diagnosis and at the time of spirometry. The laboratory
data of CD4 and viral loadwere included in the analysis if they
were done within 3 months of the spirometry.Statistical analysis
Descriptive statistics is utilized for baseline characteristics.
We used standard non parametric methods to conduct
descriptive analyses. Prevalence of smoking in HIV patients
was compared to that of the general population from
NHANES III data set report using Fisher’s exact test and Chi
square test. The actual number and estimates were used
from the NHANES III database report.21 The estimates in
this study were adjusted for unequal probabilities using
sampling weights. We used logistic regression to determine
the impact of HIV status on the risk of COPD. Models were
adjusted for age and number of pack-years of smoking.
Wealso generateda regressionmodel exploring the factors
associated with COPD in HIV-positive subjects. We calculated
odds ratio of having OLDwith age, intravenous drug use (IDU),
number of pack-years of smoking and history of pneumocystis
pneumonia (PCP). All analyses were performed using a Stata-
version 9.1; (Stata Corp; College Station, TX). A p value of
<0.05 was considered statistically significant.ResultsDemographics
One hundred and thirty nine patients were screened for
inclusion in the study. (Fig. 1) Twenty six refused to
participate, 8 were excluded for recent respiratory infec-
tion, 7 had known history of lung disease (other than
obstructive lung disease). Ninety-eight patients were
included in the final analysis. The mean age was 45 (SD 11).
Men comprised 84% of the population. The age range was
20e76. The mean age of diagnosis of HIV in this group was
37 years (SD 10). The mean duration of HIV diagnosis was 8
years (SD 6.5). The range of duration of HIV was from 0 to
29 years. The overall prevalence of smoking in this HIV
population was 55%, compared to the prevalence of
smoking in the general population of 49.6%.21 The HIV
population in our clinic compromised of mixed socioeco-
nomic status evident by their health insurance. Seventy-
two percent had private insurance, 20% were Medicare
population, and 7% were Medicaid dependent. The group
was heterogeneous in ethnic distribution with 58% being
African American, 34% Caucasian, 7% Hispanic and others
1%. To our surprise, active smokers comprised only 21% of
this HIV population.. The mean pack years among smokers
was 17.4 (SD 13.5). The mean CD4 count at nadir was 217.
Only 8% of the patients had history of IDU. Eighty-eight
percent of subjects were receiving ART. Twelve percent
were not on ART as they did not meet indication or were
non-compliant with medications. Table 2. Eleven
patients(12.5%) had HIV viral load at undetectable levels.
Figure 1 Flow diagram depicting number of patients screened and included in the study.
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report .21Our cohort showed a prevalence of 16.3% of OLD.
The prevalence was higher than that of the general pop-
ulation (RR Z 95% CI Z 1.523.77; p Z 0.001).
RR Z relative risk, CI Z Confidence interval.
Spirometery
The results of the pulmonary function test were as follows.
All 98 subjects had spirometery performed. The mean
Forced vital capacity was 4.01 L (89% predicted).
The mean FEV1 was 3.13 L, and the mean of FEV1% pre-
dicted was 88%. The prevalence of obstructive lung distur-
bance in our population was significantly higher than the
prevalence of obstructive lung disease in a historical control
group (16.3% vs. 6.8%; p value: 0.001). HIV-infected patients
who never smoked also had significantly higher prevalence of
OLD as compared to historical control patients who never
smoked (13.6% vs. 3.2%; p value: 0.003). Current and ever
smokers comprised 21% and 55%. Prevalence of OLD in HIV
patients with history of smoking was 18.5% compared to the
general population of 11%. Fischer test showed p value not to
be significant at 0.081. (Tables 2 and 3)Table 2 Baseline Demographics, laboratory and spirometry dat
Variables TotalHIV population(98)
Sex
Male 82(84%)
Female 16(16%)
Age (SD) 44.8(11.2)
CD4 Nadir (SD) 217 (193)
HIV Load At Nadir (SD) 271706(896318)
PCP Infection 22/98
Years of HIV (SD) 8.3(6.5)
Pack years (SD) 9.6(13.2)
FEV1% (SD) 87.5%(17.5)
FEV1/FVC ratio (SD) 0.78(0.07)
SGRQ score(SD) 11.6 (17)
HAART 86(87.7%)SGRQwas administered to all 98 patients. Themean SGRQ
score was 11.6 in the HIV population. Patients with OLD had
a mean of 27.7. The mean among patients with no OLD on
spirometery was 8.5. The mean SGRQ in active smokers was
17 and 15 in subjects known history of smoking.
We performed regression on FEV1% and SGRQ only in
subjects with evidence of OLD. We found this to be statis-
tically significant (The slope was 1.46 with a 95% (CI)
2.32 to 0.61 p Z 0.002.) Fig. 2.
Associations
Logistic regression analysis showed odds ratio of OLD in HIV
increased with age (1.05 95% CI 1.0e1.11), pack years of
smoking (1.05 95% CI Z 1.01e1.09), IDU (6.5. 95%
CI Z 1.43e29.5) and history of PCP infection (3.47. 95%
CI Z 1.11e10.81).Discussion
In this study we found that the prevalence of OLD among
HIV population to be significantly higher than the generala.
OLD (16) Non OLD (82) P value
13 69
3 13
50.4(13.6) 43.7(10.4) 0.081
200 (176) 220 (197) 0.69
455996(939576) 236841(890227) 0.43
7/16 15/82 0.026*
9.1(7.9) 8.1(6.2) 0.65
18.6(19.9) 7.8(10.8) 0.051
65.9%(14.2) 91.7%(14.8) 0.000*
0.67(0.03) 0.80(0.05) 0.000*
27.78(29.7) 8.45(11.1) 0.02*
13(81.2%) 73(89%)
Table 3 Smoking status and OLD according to our study
population and the NHANES III study population.
HIV Population
(%)
OLD
(%)
NHANES III
(%)
OLD
(%)
Smokers Ever 55.1 18.5 49.6 11
Current Smokers 21.4 19.0 25.4 12.5
Non Smokers 44.9 13.6 50.4 3.23
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NHANES III data set where the prevalence of OLD was 6.8%
(0.3%). OLD on spirometry in the NHANES III study was
defined similarly to our study as FEV1/FVC ratio of less than
0.7 and a FEV1 of less than 80%.
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The HIV population has traditionally been known to have
more smokers.9,22 It would seem likely that this population
would be more prone to the development of OLD as
a consequence of smoking. Our current cohort of patients
also demonstrates the health awareness of the hazards of
tobacco use. The prevalence of active smokers was less in
our population than the NHANES database.
SGRQ has been validated in patients with OLD19; it has
never been conducted in HIV patients with OLD. We have
conducted SGRQ in this population and shown that it has
linear inverse relationship.
Despite the fact that the pathogenic role of microor-
ganisms in the course of OLD is controversial,23e27
increased airflow obstruction, following to episodes of
bacterial pneumonia and PCP have been recognized in HIV-
positive patients.28 Additionally, episodes of clinical pneu-
monia or colonization with respiratory organisms may
contribute to airway obstruction.29,30
It remains unknown whether CD4 count, HIV viral load, or
ART influences the development or clinical course of OLD.
Oxidative stress may perhaps play an important part in
the development and progression of OLD, particularly in
patients who have HIV. Increased oxidative stress is
demonstrated in the lungs of patients who have COPD and
asthma greater than that seen in healthy smokers.31,32 A
decline in the ability to preserve an antioxidant shield may
enhance vulnerability to OLD.33e35 HIV-positive patients
have evidence of abnormal systemic and lung oxidant/0
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Figure 2 Relationship between SGRQ and FEV1% in HIV
patients with OLD.antioxidant stability, as found by decreased antioxidant
defenses, especially superoxide dismutase and gluta-
thione,36,37 and increased serum concentrations of lipid
peroxidation products.38 Smoking may supplement this
oxidative stress, further exhausting antioxidant protection
of the lungs in HIV-positive patients.39 Further work is
needed to illuminate which, if any, of these processes plays
a fundamental role either alone or in conjunction with
cigarette smoking or other risk factors in the pathogenesis
of OLD in HIV-positive persons.
The management of obstructive pulmonary disease in
HIV-positive patients may need closer monitoring. Indi-
vidual attention may be needed to a few key aspects of
COPD management for HIV-positive patients. First, the use
of inhaled steroids for COPD in HIV-positive patients
requires careful follow-up. HIV patients on certain ART
drugs namely Ritonavir may develop increased side effects
from steroids due to altered metabolism by inhibition of
CYP34A system.40
Till date, no studies have addressed the management of
COPD in the HIV-positive population. Given the absence of
such data, we currently follow the COPD management
guidelines proposed for HIV-negative patients.41
Furthermore, smoking cessation is of vital importance,
as current smoking is associated with increased respiratory
problems.42 Our cohort of patients showed a lower number
of active smokers than general population. This can be due
to increased counseling among our physicians to HIV
patients on the hazards of smoking.Conclusion
To our knowledge, this is the first study showing the prev-
alence of OLD in HIV population by spirometry and evalu-
ating SGRQ. HIV-positive patients from our study and
supportive literature show an increased risk for OLD,5,8,14,43
although whether this represents increased emphysema,
chronic bronchitis, other obstructive lung diseases
including asthma, or an overlap of these disorders has not
been evaluated fully. Although some of the increased OLD
may be attributable to the greater rates of smoking and
drug abuse in HIV-positive populations, the apparent risk
for OLD remains elevated in HIV patients even after
controlling for these and other potential con-
founders.5,14We have confirmed earlier observations of OLD
with spirometry measurements in a cohort of HIV patients.
Further work is needed to illuminate the pathogenesis of
OLD in HIV-positive persons, and can provide insights
pertinent to understanding COPD in general. Given the
increasing age of HIV-positive patients combined with the
high prevalence of smoking, health care providers are likely
to encounter a substantial number of HIV-positive patients
who may have OLD. Increased awareness of OLD among
health care providers of HIV-positive patients is crucial.
Recognition of OLD is important, as undiagnosed airway
obstruction is linked with impaired health and functional
status.44 Standard management of OLD is associated with
health benefits, such as decreased symptoms and COPD
exacerbations, and improved smoking cessation, exercise
capacity, and quality of life.45,46 HIV patients may repre-
sent a subset that may benefit from certain aspects in
1660 A. Hirani et al.management. Additional studies are needed to determine
whether or not the pharmacologic and non pharmacologic
management strategies for OLD should differ in HIV-positive
patients versus HIV-negative to best maintain patient
health over time. With the high prevalence of OLD seen in
our study with HIV patients, we believe that screening in
HIV population would lead in better management of patient
and overall will improve survival, and quality of life.
The pathogenesis of why HIV is a independent risk factor
for development of OLD is still unknown. Further basic
research would be needed for better understanding of the
process.
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